Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV.

Viruses - 1 Sept 2021

Gianni Tatiana, Leoni Valerio, Sanapo Mara, Parenti Federico, Bressanin Daniela, Barboni Catia, Zaghini Anna, Campadelli-Fiume Gabriella, Vannini Andrea

Abstract excerpt

We report on the efficacy of the non-attenuated HER2-retargeted oHSV named R-337 against the immunologically hot CT26-HER2 tumor, and an insight into the basis of the immune protection. Preliminarily, we conducted an RNA immune profiling and immune cell content characterization of CT26-HER2 tumor in comparison to the immunologically cold LLC1-HER2 tumor. CT26-HER2 tumor was implanted into HER2-transgenic BALB/c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus 1, Human
Share to Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Mice, Inbred BALB C

Share to Mice, Transgenic

Share to Oncolytic Viruses

Share to Receptor, ErbB-2

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 34578328
DOI: 10.3390/v13091747
PMCID: PMC8473155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV.PMID 34578328Read ↗

Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Improves Murine Cancer OutcomesSemantic proximity Read ↗

Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeuticsSemantic proximity Read ↗

Advancement insights in cancer vaccines: mechanisms, types, and clinical applicationsSemantic proximity Read ↗

COVID-19 Vaccines: Bolstering Cancer TreatmentSemantic proximity Read ↗

Cancer Vaccines: Recent Insights and Future DirectionsSemantic proximity Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccinesSemantic proximity Read ↗

Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated VacciniaSemantic proximity Read ↗

HERV-derived epitopes represent new targets for T-cell based immunotherapies in ovarian cancerSemantic proximity Read ↗

Exploring Reovirus Plasticity for Improving Its Use as Oncolytic VirusSemantic proximity Read ↗

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinomaSemantic proximity Read ↗

Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.